Mucoadhesive and thermogelling systems for vaginal drug delivery

Advanced Drug Delivery Reviews

Volumn 92, Issue , 2015, Pages 39-52

  Caramella, Carla M ^a   Rossi, Silvia ^a   Ferrari, Franca ^a   Bonferoni, Maria Cristina ^a   Sandri, Giuseppina ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

In situ gel forming systems; Methods for mucoadhesion testing; Methods for thermogelling testing; Mucoadhesive formulations; Vaginal mucosa; Vaginal secretions

Indexed keywords

ALIPHATIC COMPOUNDS; ETHYLENE; MHEALTH; NANOPARTICLES; TARGETED DRUG DELIVERY;

MUCOADHESION; MUCOADHESIVE FORMULATIONS; SITU GEL FORMING; THERMOGELLING; VAGINAL MUCOSA; VAGINAL SECRETIONS;

CONTROLLED DRUG DELIVERY;

ALGINIC ACID; CARBOMER; CARBOXYMETHYLCELLULOSE; CHITOSAN; COPOLYMER; EXCIPIENT; GUM TRAGACANTH; HYALURONIC ACID; KARAYA GUM; LACTIC ACID; LIPOSOME; MICROSPHERE; NANOPARTICLE; PECTIN; POLY(ETHYLENE OXIDE PROPYLENE OXIDE ETHYLENE OXIDE); POLYACRYLIC ACID; POLYCARBOPHIL; UNCLASSIFIED DRUG; AGENTS USED INTRAVAGINALLY; POLOXAMER; SUPPOSITORY;

ANALYTIC METHOD; BULK METHOD; CYTOTOXICITY; DRUG DELIVERY SYSTEM; EMULSION; FLOW KINETICS; GEL; GELATION; MICROCAPSULE; MOLECULAR SCALE METHOD; MUCOADHESION; OSMOLALITY; PRIORITY JOURNAL; REVIEW; SUPPOSITORY; TABLET; TEMPERATURE; THERMOGELLING SYSTEM; TIME; VAGINA PH; VISCOELASTICITY; VISCOSITY; ADMINISTRATION AND DOSAGE; BIOLOGICAL MODEL; CHEMISTRY; DRUG ABSORPTION; FEMALE; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; PHARMACEUTICS; PHARMACOKINETICS; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES; VAGINA;

ADMINISTRATION, INTRAVAGINAL; CHITOSAN; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MODELS, BIOLOGICAL; NANOPARTICLES; POLOXAMER; SUPPOSITORIES; TECHNOLOGY, PHARMACEUTICAL; VAGINA; VAGINAL ABSORPTION; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84943456474     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.02.001     Document Type: Review

References (156)

1. Sandri G., Rossi S., Ferrari F., Bonferoni M.C., Caramella C. Strategies to improve systemic and local availability of drugs administered via vaginal route. Enhancement in Drug Delivery 2007, 441-470. Taylor and Francis CRC Press, Boca Raton FL. E. Touitou, B.W. Barry (Eds.).
2. Wolf D.P., Blasco L., Khan M.A., Litt M. Human cervical mucus. IV. Viscoelasticity and sperm penetrability during the ovulatory menstrual cycle. Fertil. Steril. 1978, 30:163-169.
3. Owen D.H., Katz D.F. A vaginal fluid simulant. Contraception 1999, 59:91-95.
4. Valenta C. The use of mucoadhesive polymers in vaginal delivery. Adv. Drug Deliv. Rev. 2005, 57:1692-1712.
5. Chappell C.A., Rohan L.C., Moncla B.J., Wang L., Meyn L.A., Bunge K., Hillier S.L. The effect of reproductive hormones on the physical properties of cervicovaginal fluid. Am. J. Obstet. Gynecol. 2014, 211:226.e1-7. 10.1016/j.ajog.2014.03.041.
6. Cribby S., Taylor M., Reid G. Vaginal microbiota and the use of probiotics. Interdiscip. Perspect. Infect. Dis. 2008, 2008. (Article ID 256490, 9 pp.).
7. Boddupalli B.M., Mohammed Z.N.K., Nath R.r A., Banji D. Mucoadhesive drug delivery system: an overview. J. Adv. Pharm. Technol. Res. 2010, 1:381-387.
8. Smart J.D. The basics and underlying mechanisms of mucoadhesion. Adv. Drug Deliv. Rev. 2005, 57:1556-1568.
9. das Neves J., Bahia M.F. Gels as vaginal drug delivery systems. Int. J. Pharm. 2006, 318:1-14.
10. Acarturk F. Mucoadhesive vaginal drug delivery systems. Recent Pat. Drug Deliv. Formul. 2009, 3:193-205.
11. Fevola M.J., Gentner L., Ahmad N., Librizzi J.J. Getting intimate with polymers: personal lubricants. Cosmet. Toilet. 2008, 123:59-68.
12. Sutton K.S., Boyer S.C., Goldfinger C., Ezer P., Pukall C.F. To lube or not to lube: experiences and perceptions of lubricant use in women with and without dyspareunia. J. Sex. Med. 2012, 9:240-250.
13. Nachtigall L.E. Comparative study: Replens™ versus local estrogen in menopausal women. Fertil. Steril. 1994, 61:178-180.
14. Wu J.P., Fielding S.L., Fiscella K. The effect of polycarbophil gel (Replens™) on bacterial vaginosis: a pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2007, 130:132-136.
15. Ahmad F.J., Alam M.A., Khan Z.I., Khar R.K., Ali M. Development and in vitro evaluation of an acid buffering bioadhesive vaginal gel for mixed vaginal infections. Acta Pharma. 2008, 58:407-419.
16. Bonferoni M.C., Giunchedi P., Scalia S., Rossi S., Sandri G., Caramella C. Chitosan gels for the vaginal delivery of lactic acid: relevance of formulation parameters to mucoadhesion and release mechanisms. AAPS PharmSciTech 2006, 7. (Article 104 (http://www.aapspharmscitech.org)).
17. Amaral E., Perdigao A., Souza M.H., Mauck C., Waller D., Zaneveld L., Faundes A. Postcoital testing after the use of a bio-adhesive acid buffering gel (ACIDFORM) and a 2% nonoxynol-9 product. Contraception 2004, 70:492-497.
18. El-Gizawy S.A., Aglan N.I. Formulation and evaluation of metronidazole acid gel for vaginal contraception. J. Pharm. Pharmacol. 2003, 55:903-909.
19. Senyiğit Z.A., Karavana S.Y., Eraç B., Gürsel O., Limoncu M.H., Baloğlu E. Evaluation of chitosan based vaginal bioadhesive gel formulations for antifungal drugs. Acta Pharma. 2014, 64:139-156.
20. Perioli L., Ambrogi V., Venezia L., Pagano C., Ricci M., Rossi C. Chitosan and a modified chitosan as agents to improve performances of mucoadhesive vaginal gels. Colloids Surf. B: Biointerfaces 2008, 66:141-145.
21. Sandri G., Rossi S., Ferrari F., Bonferoni M.C., Muzzarelli C., Caramella C. Assessment of chitosan derivatives as buccal and vaginal penetration enhancers. Eur. J. Pharm. Sci. 2004, 21:351-359.
22. Bonferoni M.C., Sandri G., Rossi S., Ferrari F., Gibin S., Caramella C. Chitosan citrate as multifunctional polymer for vaginal delivery. Evaluation of penetration enhancement and peptidase inhibition properties. Eur. J. Pharm. Sci. 2008, 33:166-176.
23. Geonnotti A.R., Peters J.J., Katz D.F. Erosion of microbicide formulation coating layers: effect of contact and shearing with vaginal fluid or semen. J. Pharm. Sci. 2005, 94:1705-1712.
24. Owen D.H., Peters J.J., Lavine M.L., Katz D.F. Effect of temperature and pH on contraceptive gel viscosity. Contraception 2003, 67:57-64.
25. Barnhart K.T., Pretorius E.S., Shera D.M., Shabbout M., Shaunik A. The optimal analysis of MRI data to quantify the distribution of a microbicide. Contraception 2006, 73:82-87.
26. Barnhart K.T., Pretorius E.S., Timbers K., Shera D., Shabbout M., Malamud D. In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse. Contraception 2004, 70:498-505.
27. Mauck C.K., Katz D., Sandefer E.P., Nasution M.D., Henderson M., Digenis G.A., Su I., Page R., Barnhart K. Vaginal distribution of Replens® and K-Y® jelly using three imaging techniques. Contraception 2008, 77:195-204.
28. Henderson M.H., Couchman G.M., Walmer D.K., Peters J.J., Owen D.H., Brown M.A., Lavine M.L., Katz D.F. Optical imaging and analysis of human vaginal coating by drug delivery gels. Contraception 2007, 75:142-151.
29. Garg S., Goldman D., Krumme M., Rohan L.C., Smoot S., Friend D.R. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antivir. Res. 2010, 88S:S19-S29.
30. Cevher E., Açma A., Sinani G., Aksu B., Zloh M., Mülazimoğlu L. Bioadhesive tablets containing cyclodextrin complex of itraconazole for the treatment of vaginal candidiasis. Int. J. Biol. Macromol. 2014, 69:124-136.
31. Alam M.A., Ahmad F.J., Khan Z.I., Khar R.K., Ali M. Development and evaluation of acid-buffering bioadhesive vaginal tablet for mixed vaginal infections. AAPS PharmSciTech 2007, 8. (E 109 (http://www.aapspharmscitech.org.)). 10.1208/pt0804109.
32. Wang L., Tang X. A novel ketoconazole bioadhesive effervescent tablet for vaginal delivery: design, in vitro and 'in vivo' evaluation. Int. J. Pharm. 2008, 350:181-187.
33. Woolfson A.D., Umrethia M.L., Kett V.L., Malcolm R.K. Freeze-dried, mucoadhesive systems for vaginal delivery of the HIV microbicide, dapirivine: optimization by an artificial neural network. Int. J. Pharm. 2010, 388:136-143.
34. Abruzzo A., Bigucci F., Cerchiara T., Saladini B., Gallucci M.C., Cruciani F., Vitali B., Luppi B. Chitosan/alginate complexes for vaginal delivery of chlorhexidine digluconate. Carbohydr. Polym. 2013, 91:651-658.
35. Baloglu E., Ay Senyiqit Z., Karavana S.Y., Vetter A., Metin D.Y., Hilmioglu Polat S., Guneri T., Bernkop-Schnurch A. In vitro evaluation of mucoadhesive vaginal tablets of antifungal drugs prepared with thiolated polymer and development of a new dissolution technique for vaginal formulations. Chem. Pharm. Bull. 2011, 59:952-958.
36. Szymanska E., Winnicka K., Amelian A., Cwalina U. Vaginal chitosan tablets with clotrimazole-design and evaluation of mucoadhesive properties using porcine vaginal mucosa, mucin and gelatine. Chem. Pharm. Bull. 2014, 62:160-167.
37. Rastogi R., Teller R.S., Mesquita P.M.M., Herold B.C., Kiser P.F. Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa. Antivir. Res. 2013, 100:255-258.
38. Perioli L., Ambrogi V., Venezia L., Pagano C., Giovagnoli S., Rossi C. Formulation studies of benzydamine mucoadhesive formulations for vaginal administration. Drug Dev. Ind. Pharm. 2009, 35:769-779.
39. Friedman D., Schwarz J., Amselem S. Submicron Emulsions for Delivery of Peptides, US5514670 1995.
40. Putteman P., Francois M.K.J., Snoeckx E.C.L. Mucoadhesive Emulsions Containing Cyclodextrin US 5814330 A 1998.
41. Kirschner M., Levinson R., Riley T., Hermelin M. Bioadhesive Drug Delivery System US 20030180366 A1 2003.
42. Geraghty P.B., Attwood D., Collett J.H., Dandiker Y. The in vitro release of some antimuscarinic drugs from monoolein/water lyotropic liquid crystalline gels. Pharm. Res. 1996, 13:1265-1271.
43. Geraghty P.B., Attwood D., Collett J.H., Sharma H., Dandiker Y. An investigation of the parameters influencing the bioadhesive properties of Myverol 18-99/water gels. Biomaterials 1997, 18:63-67.
44. Albertini B., Passerini N., Di Sabatino M., Vitali B., Brigidi P., Rodriguez L. Polymer-lipid based mucoadhesive microspheres prepared by spray-congealing for the vaginal delivery of econazole nitrate. Eur. J. Pharm. Sci. 2009, 36:591-601.
45. Martin-Villena M.J., Fernandez-Campos F., Calpena-Campmany A.C., Bozal-de Febrer N., Ruiz-Martinez M.A., Clares-Naveros B. Novel microparticulate systems for the vaginal delivery of nystatin: development and characterization. Carbohydr. Polym. 2013, 94:1-11.
46. Richardson J.L., Whetstone J., Fisher N.F., Watts P., Farraj N.F., Hinchcliffe M., Benedetti L., Illum L. Gamma scintigraphy as a novel method to study the distribution and retention of a bioadhesive vaginal delivery system in sheep. J. Control. Release 1996, 42:133-142.
47. Richardson J.L., Ramires P.A., Miglietta M.R., Rochira M., Bacelle L., Callegaro L., Bedetti L. Novel vaginal delivery systems for calcitonin: I. Evaluation of HYAFF/calcitonin microspheres in rats. Int. J. Pharm. 1995, 115:9-15.
48. Sanzgiri Y.D., Topp E.M., Benedetti L., Stella V.J. Evaluation of mucoadhesive properties of hyaluronic acid benzyl esters. Int. J. Pharm. 1994, 107:91-97.
49. das Neves J., Amiji M., Sarmento B. Mucoadhesive nanosystems for vaginal microbicide development: friend or foe?. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2011, 3:389-399.
50. Ensign L., Cone R., Hanes J. Nanoparticle-based drug delivery to the vagina: a review. J. Control. Release 2014, 190:500-514.
51. Cone R.A. Barrier properties of mucus. Adv. Drug Deliv. Rev. 2009, 61:75-85.
52. Ponchel G., Montisci M.J., Dembri A., Durrer C., Duchene D. Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract. Eur. J. Pharm. Biopharm. 1997, 44:25-31.
53. Suh J., Dawson M., Hanes J. Real-time multiple-particle tracking: applications to drug and gene delivery. Adv. Drug Deliv. Rev. 2005, 57:63-78.
54. Lai S.K., O'Hanlon D.E., Harrold S., Man S.T., Wang Y.Y., Cone R., Hanes J. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:1482-1487.
55. Wang Y.Y., Lai S.K., Suk J.S., Pace A., Cone R., Hanes J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the humanmucus barrier. Angew. Chem. Int. Ed. Engl. 2008, 47:9726-9729.
56. McGill S., Smyth H. Disruption of the mucus barrier by topically applied exogenous particles. Mol. Pharm. 2010, 7:2280-2288.
57. Ensign L.M., Tang B.C., Wang Y.Y., Tse T.A., Hoen T., Cone R., Hanes J. Mucus penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci. Transl. Med. 2012, 4:138-179.
58. Lackman-Smith C., Osterling C., Luckenbaugh K., Mankowski M., Snyder B., Lewis G., Paull J., Profy A., Ptak R.G., Buckheit R.W., Watson K.M., Cummings J.E., Sanders-Beer B.E. Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob. Agents Chemother. 2008, 52:1768-1781.
59. Whaley K.J., Hanes J., Shattock R., Cone R.A., Friend D.R. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antivir. Res. 2010, 88(Suppl. 1):S55-S66.
60. Tang B.C., Dawson M., Lai S.K., Wang Y.Y., Suk J.S., Yang M., Zeitlin P., Boyle M.P., Fu J., Hanes J. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:19268-19273.
61. Boukari H., Brichacek B., Stratton P., Mahoney S.F., Lifson J.D., Margolis L., Nossal R. Movements of HIV virions in human cervical mucus. Biomacromolecules 2009, 10:2482-2488.
62. Lai S.K., Wang Y.Y., Hida K., Cone R., Hanes J. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:598-603.
63. Willits R.K., Saltzman W.M. Synthetic polymers alter the structure of cervical mucus. Biomaterials 2001, 22:445-452.
64. Chen E.Y., Wang Y.C., Chen C.S., Chin W.C. Functionalized positive nanoparticles reduce mucin swelling and dispersion. PLoS One 2010, 5:e15434.
65. Gupta K.M., Barnes S.R., Tangaro R.A., Roberts M.C., Owen D.H., Katz D.F., Kiser P.F. Temperature and pH sensitive hydrogels: an approach towards smart semen triggered vaginal microbicidal vehicles. J. Pharm. Sci. 2007, 96:670-681.
66. Yoo J.W., Giri N., Lee C.H. pH-sensitive Eudragit nanoparticles for mucosal drug delivery. Int. J. Pharm. 2011, 403:262-267.
67. Lai S.K., Hida K., Shukair S., Wang Y.Y., Figueiredo A., Cone R., Hope T.J., Hanes J. Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J. Virol. 2009, 83:11196-11200.
68. Olmsted S.S., Padgett J.L., Yudin A.I., Whaley K.J., Moench T.R., Cone R.A. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys. J. 2001, 81:1930-1937.
69. Cu Y., Booth C.J., Saltzman W.M. In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. J. Control. Release 2011, 156:258-264.
70. Yang M., Yu T., Wang Y.Y., Lai S.K., Zeng Q., Miao B., Tang B.C., Simons B.W., Ensign L.M., Liu G., Chan K.W., Juang C.Y., Mert O., Wood J., Fu J., McMahon M.T., Wu T.C., Hung C.F., Hanes J. Vaginal delivery of paclitaxel via nanoparticles with non-nucoadhesive surfaces suppresses cervical tumor growth. Adv. Healthcare Mater. 2014, 3:1044-1052.
71. Pavelic Z., Skalko-Basnet N.S., Filipovic-Grcic J., Martinac A., Jalsenjak I. Development an in vitro evaluation of a liposomal vaginal delivery systems for acyclovir. J. Control Release 2005, 106:34-43.
72. Bergin K., Suljaković S., Škalko-Basnet N., Kristl A. Mucoadhesive liposomes as new formulation for vaginal delivery of curcumin. Eur. J. Pharm. Biopharm. 2014, 87:40-46.
73. Tamburic S., Craig D.Q.M. A comparison of different in vitro methods for measuring mucoadhesive performance. Eur. J. Pharm. Biopharm. 1997, 44(2):159-167.
74. Grabovac V., Gucci D., Bernkop-Schnurch A. Comparison of the mucoadhesive properties of various polymers. Adv. Drug Deliv. Rev. 2005, 57:1713-1723.
75. Edsman K., Hägerström H. Pharmaceutical application of mucoadhesion for the non-oral routes. J. Pharm. Pharmacol. 2005, 57:3-22.
76. das Neves J., Amaral M.H., Bahia M.F. Performance of in vitro mucoadhesion testing method for vaginal semisolids: influence of different testing conditions and instrumental apparatus. Eur. J. Pharm. Biopharm. 2008, 69:622-632.
77. Hägerström H., Bergström C.A.S., Edsman K. The importance of gel properties for mucoadhesion measurements: a multivariate analysis approach. J. Pharm. Pharmacol. 2004, 56:161-168.
78. Bonferoni M.C., Sandri G., Ferrari F., Rossi S., Larghi V., Zambito Y., Caramella C. Comparison of different in vitro and ex vivo methods to evaluate mucoadhesion of glicol-palmitoyl chitosan micelles. J. Drug Deliv. Sci. Technol. 2010, 20:419-424.
79. Hassan E.E., Gallo J.M. A simple rheological method for the in vitro assessment of mucin-polymer bioadhesive bond strength. Pharm. Res. 1990, 7:491-495.
80. Caramella C., Bonferoni M.C., Rossi S., Ferrari F. Rheological and tensile tests for the assessment of polymer-mucin interactions. Eur. J. Pharm. Biopharm. 1994, 40:213-217.
81. Caramella C.M., Rossi S., Bonferoni M.C. A rheological approach to explain the mucoadhesive behaviour of polymer hydrogel. Bioadhesive Drug Delivery Systems. Fundamental, Novel Approaches and Development 1999, 25-65. Marcel Dekker Inc., New York. E. Mathiowitz, D.E. Chickering, C.M. Lehr (Eds.).
82. Rossi S., Bonferoni M.C., Caramella C., Ironi L., Tentoni S. Model-based interpretation of creep profiles for the assessment of polymer-muycin interaction. Pharm. Res. 1999, 16:1456-1463.
83. Ferrari F., Rossi S., Martini A., Muggetti L., De Ponti R., Caramella C. Technological induction of mucoadhesive properties on waxy starches by grinding. Eur. J. Pharm. Sci. 1997, 5:277-285.
84. Rossi S., Bonferoni M.C., Lippoli G., Bertoni M., Ferrari F., Caramella C., Conte U. Influence of mucin type on polymer-mucin rheological interactions. Biomaterials 1995, 16:1073-1079.
85. Sandri G., Rossi S., Bonferoni M.C., Ferrari F., Mori M., Caramella C. The role of chitosan as a mucoadhesive agent in mucosal drug delivery. J. Drug Deliv. Sci. Technol. 2012, 22:275-284.
86. Madsen F., Eberth K., Smart J.D. A rheological assessment of the nature of interactions between mucoadhesive polymers and a homogenised mucus gel. Biomaterials 1998, 19:1083-1092.
87. Rossi S., Ferrari F., Bonferoni M.C., Caramella C. Characterization of chitosan hydrochloride-mucin interaction by means of viscosimetric and turbidimetric measurements. Eur. J. Pharm. Sci. 2000, 10:251-257.
88. Rossi S., Ferrari F., Bonferoni M.C., Caramella C. Characterization of chitosan hydrochloride-mucin rheological interaction: influence of polymer concentration and polymer:mucin weight ratio. Eur. J. Pharm. Sci. 2001, 12:479-485.
89. Peh K.K., Wong C.F. Polymeric films as vehicle for buccal delivery: swelling, mechanical and bioadhesive properties. J. Pharm. Pharm. Sci. 1999, 2:53-61.
90. Abd ElHady S.S., Mortada N.D., Awad G.A.S., Zaki N.M., Taha R.A. Development of in situ gelling and mucoadhesive mebeverine hydrochloride solution for rectal administration. Saudi Pharm. J. 2003, 11:159-171.
91. Ferrari F., Rossi S., Bonferoni M.C., Caramella C., Karlsen J. Characterization of rheological and mucoadhesive properties of three grades of chitosan hydrochloride. Farmaco 1997, 52(6-7):493-497.
92. Rossi S., Sandri G., Ferrari F., Bonferoni M.C., Caramella C. Buccal delivery of acyclovir from films based on chitosan and polyacrylic acid. Pharm. Dev. Technol. 2003, 8:199-208.
93. Rossi S., Sandri G., Ferrari F., Bonferoni M.C., Caramella C. Development of films and matrices based on chitosan and polyacrylic acid for vaginal delivery of acyclovir. STP Pharma. Sci. 2003, 13:181-189.
94. Smart J.D., Kellaway I.W., Worthington H.E. An in-vitro investigation of mucosa-adhesive materials for use in controlled drug delivery. J. Pharm. Pharmacol. 1984, 36:295-299.
95. Puccio A., Ferrari F., Rossi S., Bonferoni M.C., Sandri G., Dacarro C., Grisoli P., Caramella C. Comparison of functional and biological properties of chitosan and hyaluronic acid to be used for the treatment of mucositis in cancer patients. J. Drug Deliv. Sci.Technol. 2011, 21:241-247.
96. Rossi S., Marciello M., Ferrari F., Puccio A., Bonferoni M.C., Sandri G., Caramella C. Development of sponge-like dressings for mucosal/transmucosal drug delivery into vaginal cavity. Pharm. Dev. Technol. 2012, 17:219-222.
97. Rossi S., Ferrari F., Bonferoni M.C., Sandri G., Faccendini A., Puccio A., Caramella C. Comparison of poloxamer- and chitosan-based thermally sensitive gels for the treatment of vaginal mucositis. Drug Dev. Ind. Pharm. 2014, 40:352-360.
98. Sandri G., Bonferoni M.C., Ferrari F., Rossi S., Del Fante C., Perotti C., Gallanti A., Caramella C. An in situ gelling buccal spray containing platelet lysate for the treatment of oral mucositis. Curr. Drug Discov. Technol. 2011, 8:277-285.
99. Bonferoni M.C., Rossi S., Ferrari F., Caramella C. A modified Franz diffusion cell for simultaneous assessment of drug release and washability of mucoadhesive gel. Pharm. Dev. Technol. 1999, 4:45-54.
100. Rossi S., Bonferoni M.C., Ferrari F., Caramella C. Drug release and washability of mucoadhesive gels based on sodium carboxymethylcellulose and polyacrylic acid. Pharm. Dev. Technol. 1999, 4:55-63.
101. Sandri G., Bonferoni M.C., Rossi S., Ferrari F., Gibin S., Zambito Y., Di Colo G., Caramella C. Nanoparticles based on N-trimethylchitosan: evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models. Eur. J. Pharm. Biopharm. 2007, 65:68-77.
102. Takeuchi H., Thongborisute J., Matsui Y., Sugihara H., Yamamoto H., Kawashima Y. Novel mucoadhesion tests for polymers and polymer coated particles to design optimal mucoadhesion drug delivery systems. Adv. Drug Deliv. Rev. 2005, 57:1583-1594.
103. Bansil R., Turner B.S. Mucin structure, aggregation, physiological functions and biomedical applications. Curr. Opin. Colloid Interface Sci. 2006, 11:164-170.
104. Mugabe C., Hadaschik B.A., Kainthan R.K., Brooks D.E., So A.I., Gleave M.E., Burt H.M. Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerol of intravesical bladder cancer therapy. BJU Int. 2009, 103:978-986.
105. Jintapattanakit A., Junyaprasert V.B., Kissel T. The role of mucoadhesion of trimethyl chitosan and PEGylated trimethyl chitosan nanocomplexes in insulin uptake. J. Pharm. Sci. 2009, 998:4818-4830.
106. Svensson O., Thuresson K., Arnebrant T. Interactions between drug delivery particles and mucin in solution and at interfaces. Langmuir 2008, 24:2573-2579.
107. Svensson O., Thuresson K., Arnebrant T. Interactions between chitosan-modified particles and mucin-coated surfaces. J. Colloid Interface Sci. 2008, 325:346-350.
108. Lopedota A., Trapani A., Cutrignelli A., Chiarantini L., Pantucci E., Curci R., Manuali E., Trapani G. The use of Eudragit RS® 100/cyclodextrin nanoparticles for the transmucosal administration of gluthatione. Eur. J. Pharm. Biopharm. 2009, 72:509-520.
109. Ramteke S., Ganesh N., Battacharja S., Narendra K.J. Triple therapy-based targeted nanoparticles for the treatment of Helicobacter pylori. J. Drug Target. 2008, 16:694-705.
110. Chayed S., Winnik F.M. In vitro evaluation of the mucoadhesive properties of polysaccharide-based nanoparticulate oral drug delivery systems. Eur. J. Pharm. Biopharm. 2007, 65:363-370.
111. Crater J.S., Carrier R.L. Barrier properties of gastrointestinal mucus to nanoparticle transport. Macromol. Biosci. 2010, 10:1473-1483.
112. Lamprecht A., Koenig P., Ubrich N., Maincent P., Neumann D. Low molecular weight heparin nanoparticles: mucoadhesion and behaviour in Caco-2 cells. Nanotechnology 2006, 17:3673-3680.
113. Park K., Robinson J.R. Bioadhesive polymers as platforms for oral-controlled drug delivery: method to study bioadhesion. Int. J. Pharm. 1984, 19:107-127.
114. Makhlof A., Werle M., Tozuka Y., Takeuchi H. A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa. J. Control. Release 2011, 149:81-88.
115. Wirth M., Kneuer C., Lehr C.M., Gabor F. Lectin-mediated drug delivery: discrimination between cyctoadhesion and cytoinvasion and evidence for lysosomal accumulation of wheat germ agglutinin in the Caco-2 model. J. Drug Target. 2002, 10:439-448.
116. Fillafer C., Friedl D.S., Wirth M., Gabor F. Fluorescent bionanoprobes to characterize cytoadhesion and cytoinvasion. Small 2008, 4:627-633.
117. Ruel-Gariepy E., Leroux J.C. In situ-forming hydrogels-review of temperature-sensitive systems. Eur. J. Pharm. Biopharm. 2004, 58:409-426.
118. Liu Y., Zhu Y., Wei G., Lu W. Effect of carrageenan on poloxamer-based in situ gel for vaginal use: improved in vitro and in vivo sustained-release properties. Eur. J. Pharm. Sci. 2009, 37:306-312.
119. Ibrahim E.I., Fetih G., Shaaban O., Hassanein K., Abdellah N.H. Development and characterization of thermosensitive pluronic-based metronidazole in situ gelling formulations for vaginal application. Acta Pharma. 2012, 62:59-70.
120. Kim Y.T., Shina B.-K., Garripelli V.K., Kimb J.-K., Davaaa E., Jo S., Parka J.-S. A thermosensitive vaginal gel formulation with HP CD for the pH-dependent release and solubilization of amphotericin B. Eur. J. Pharm. Sci. 2010, 41:399-406.
121. Edsman K., Carlfors J., Petersson R. Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur. J. Pharm. Sci. 1998, 6:105-112.
122. Dumortier G., Grossiord J.L., Agnely F., Chaumeil J.C. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm. Res. 2006, 23:2709-2728.
123. Escobar-Chávez J.L., López-Cervantes M., Naïk A., Kalia Y.N., Quintanar-Guerrero D., Ganem-Quintanar A. Applications of thermoreversible Pluronic F-127 gels in pharmaceutical formulations. J. Pharm. Pharm. Sci. 2006, 9:339-358.
124. Liu Y., Lu W.-L., Wang J.-C., Zhang X., Zhang H., Wang X.-Q., Zhou T.-Y., Zhang Q. Controlled delivery of recombinant hirudin based on thermo-sensitive Pluronic® F127 hydrogel for subcutaneous administration: in vitro and in vivo characterization. J. Control. Release 2007, 117:387-395.
125. Yang Y., Wang J., Zhang X., Lu W., Zhang Q. A novel mixed micelle gel with thermosensitive property for the local delivery of docetaxel. J. Control. Release 2009, 135:175-182.
126. Patel H.R., Patel M.M. Poloxamers: a pharmaceutical excipients with therapeutic behaviors. Int. J. PharmTech Res. 2009, 1(2):299-303.
127. Kang J.-W., Davaa E., Kim Y.-T., Park J.-S. A new vaginal delivery system of amphotericin B: a dispersion of cationic liposomes in a thermosensitive gel. J. Drug Target. 2010, 18:637-644.
128. Kumar K.J., Jayachandran E., Srinivas G.M., Giridhar B., Nair R., Jayakandan M. A novel thermo-sensitive sol-gel reversible buccal adhesive property of fluconazole in situ gel for oral thrush. J. Biomed. Sci. Res. 2010, 2:92-101.
129. Xuan J.-J., Yan Y.D., Oh D.H., Choi Y.K., Yong C.S., Choi H.G. Development of thermosensitive injectable hydrogel with sustained release of doxorubicin: rheological characterization and in vivo evaluation in rats. Drug Deliv. 2011, 18:305-311.
130. Chang J.Y., Oh Y.-K., Choi H., Kim Y.B., Kim C.-K. Rheological evaluation of thermosensitive and mucoadhesive vaginal gels in physiological conditions. Int. J. Pharm. 2002, 241:155-163.
131. Lin H.R., Sung K.C., Vong W.J. In situ gelling of alginate/pluronic solutions for ophthalmic delivery of pilocarpine. Biomacromolecules 2004, 6:2358-2365.
132. Bilensoy E., Rouf M.A., Vural I., Şen M., Hincal A.A. Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole:β-cyclodextrin complex. AAPS PharmSciTech 2006, 7(2). (Article 38 (http://www.aapspharmscitech.org)).
133. Qi H., Chen W., Huang C., Li L., Chen C., Li W., Wu C. Development of poloxameranalogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int. J. Pharm. 2007, 337:178-187.
134. Mayol L., Quaglia F., Borzacchiello A., Ambrosio L., La Rotonda M.I. A novel poloxamers/hyaluronic acid in situ forming hydrogel for drug delivery: rheological, mucoadhesive and in vitro release properties. Eur. J. Pharm. Biopharm. 2008, 70:199-206.
135. Koffi A.A., Agnely F., Besnard M., Kablan Brou J., Grossiord J.L., Ponchel G. In vitro and in vivo characteristics of a thermogelling and bioadhesive delivery system intended for rectal administration of quinine in children. Eur. J. Pharm. Biopharm. 2008, 69:167-175.
136. Aka-Any-Grah A., Bouchemal K., Koffi A., Zhang M., Djabourov M., Ponchel G. Formulation of mucoadhesive vaginal hydrogels insensitive to dilution with vaginal fluids. Eur. J. Pharm. Biopharm. 2010, 76:296-303.
137. Gratieri T., Gelfuso Martins M., de Freitas O., Melani Rocha E., Lopez R.F.V. Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer/chitosan in situ forming gel. Eur. J. Pharm. Biopharm. 2011, 79:320-327.
138. Karavana S.Y., Rençber S., Şenyiğit Z.A., Baloğlu E. A new in-situ gel formulation of itraconazole for vaginal administration. Pharmacol. Pharm. 2012, 3:417-426.
139. Date A., Shibata A., Goede M., Sanford B., La Bruzzo K., Belshan M., Destache C.J. Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis. Antivir. Res. 2012, 96:430-436.
140. Hani U., Shivakamuar H.G. Development of miconazole nitrate thermosensitive bioadhesive vaginal gel for vaginal candidiasis. Am. J. Adv. Drug Deliv. 2013, 3:358-368.
141. Garripelli V.K., Kim J.-K., Namgung R., Kim W.J., Repka M.A., Jo S. A novel thermosensitive polymer with pH-depedent degradation for drug delivery. Acta Biomater. 2010, 6:477-485.
142. Chenite A., Chaput C., Wang D., Combes C., Buschmann M.D., Hoemann C.D., Leroux J.C., Atkinson B.L., Binette F., Selmani A. Novel injectable neutral solution of chitosan form biodegradable gel, in situ. Biomaterials 2000, 2:2155-2161.
143. Chenite A., Buschmann M.D., Wang D., Chaput C., Kandani N. Rheological characterization of thermogelling chitosan/glycerophosphate solutions. Carboydr. Polym. 2001, 46:39-47.
144. Ganguly S., Dash A.K. A novel in situ gel for sustained drug delivery and targeting. Int. J. Pharm. 2004, 276:83-92.
145. Ruel-Gariépy E., Shive M., Bichar A., Berrada M., Le Garrec D., Chenite A., Leroux J.C. A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel. Eur. J. Pharm. Biopharm. 2004, 57:53-63.
146. Lavertu M., Filion D., Buschmann M.D. Heat-induced transfer of protons from chitosan to glycerol phosphate produces chitosan precipitation and gelation. Biomacromolecules 2008, 9:640-650.
147. Rossi S., Marciello M., Bonferoni M.C., Ferrari F., Sandri G., Dacarro C., Grisoli P., Caramella C. Thermally sensitive gels based on chitosan derivatives for the treatment of oral mucositis. Eur. J. Pharm. Biopharm. 2010, 74:248-254.
148. WHO/UNFPA/FHI Use and Procurement of Additional Lubricants for Male and Female Condoms: WHO/UNFPA/FHI 2012, WHO, Geneva, Switzerland.
149. Fiorilli A., Molteni B., Milani M. Successful treatment of bacterial vaginosis with a policarbophil-carbopol acidic vaginal gel: results from a randomised double-blind, placebo-controlled trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 2005, 120:202-205.
150. Cunha A.R., Machado R.M., Palmeira-de-Oliveira A., Martinez-de-Oliveira J., das Neves J., Palmeira-de-Oliveira R. Characterization of commercially available vaginal lubricants:a safety perspective. Pharmaceutics 2014, 6:530-542.
151. Trifonova T.R., Pasicznyk J.-M., Fichorova R.N. Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo. Antimicrob. Agents Chemother. 2006, 50:4005-4010.
152. Warrier B.K., Kostoryz E., Lee C.H. Biocompatibility of components of a female controlled drug delivery systems. J. Biomed. Mater. Res. A 2004, 71A:209-216.
153. Mahalingam A., Simmons A.P., Ugaonkar S.R., Watson K.M., Dezzutti C.S., Rohan L.C., Buckheit R.W., Kiser P.F. Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob. Agents Chemother. 2011, 55:1650-1660.
154. Rohan L.C., Moncla B.J., Kunjara Na Ayudhya R.P., Cost M., Huang Y., Gai F., Billitto N., Lynam J.D., Pryke K., Graebing P., Hopkins N., Rooney J.F., Friend D., Dezzutti C.S. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 2010, 5:e9310.
155. Dezzutti C.S., Rohan L.C., Wang L., Uranker K., Shetler C., Cost M., Lynam J.D., Friend D. Reformulated tenofovir gel for use as a dual compartment microbicide. J. Antimicrob. Chemother. 2012, 67:2139-2142.
156. Grammen C., Arien K.K., Venkatraj M., Joossens J., van der Veken P., Heeres J., Lewi P.J., Haenen S., Augustyns K., Vanham G., Augustijns P., Brouwers J. Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1. Antivir. Res. 2014, 101:113-121.